Norway · Delayed Price · Currency is NOK Oncoinvent ASA Statistics
Total Valuation
Oncoinvent ASA has a market cap or net worth of NOK 602.35 million. The enterprise value is 497.61 million.
| Market Cap | 602.35M |
| Enterprise Value | 497.61M |
Important Dates
The last earnings date was Thursday, August 27, 2026.
| Earnings Date | Aug 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Oncoinvent ASA has 4.48 million shares outstanding. The number of shares has increased by 403.80% in one year.
| Current Share Class | 4.48M |
| Shares Outstanding | 4.48M |
| Shares Change (YoY) | +403.80% |
| Shares Change (QoQ) | +198.35% |
| Owned by Insiders (%) | 1.27% |
| Owned by Institutions (%) | 6.73% |
| Float | 2.44M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 24.78 |
| PB Ratio | 7.47 |
| P/TBV Ratio | 7.47 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 20.47 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.43, with a Debt / Equity ratio of 0.03.
| Current Ratio | 2.43 |
| Quick Ratio | 2.43 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.02 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -228.06% and return on invested capital (ROIC) is -138.39%.
| Return on Equity (ROE) | -228.06% |
| Return on Assets (ROA) | -94.22% |
| Return on Invested Capital (ROIC) | -138.39% |
| Return on Capital Employed (ROCE) | -217.40% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 578,857 |
| Profits Per Employee | -4.08M |
| Employee Count | 42 |
| Asset Turnover | 0.21 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 84.79 |
| 200-Day Moving Average | 56.54 |
| Relative Strength Index (RSI) | 83.30 |
| Average Volume (20 Days) | 16,066 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Oncoinvent ASA had revenue of NOK 24.31 million and -171.16 million in losses. Loss per share was -57.11.
| Revenue | 24.31M |
| Gross Profit | 24.31M |
| Operating Income | -175.31M |
| Pretax Income | -171.16M |
| Net Income | -171.16M |
| EBITDA | -167.29M |
| EBIT | -175.31M |
| Loss Per Share | -57.11 |
Balance Sheet
The company has 106.77 million in cash and 2.04 million in debt, with a net cash position of 104.74 million or 23.39 per share.
| Cash & Cash Equivalents | 106.77M |
| Total Debt | 2.04M |
| Net Cash | 104.74M |
| Net Cash Per Share | 23.39 |
| Equity (Book Value) | 80.64M |
| Book Value Per Share | 18.01 |
| Working Capital | 68.06M |
Cash Flow
In the last 12 months, operating cash flow was -132.58 million and capital expenditures -154,000, giving a free cash flow of -132.74 million.
| Operating Cash Flow | -132.58M |
| Capital Expenditures | -154,000 |
| Depreciation & Amortization | 8.02M |
| Net Borrowing | -2.60M |
| Free Cash Flow | -132.74M |
| FCF Per Share | -29.64 |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -721.06% |
| Pretax Margin | -704.00% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Oncoinvent ASA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -403.80% |
| Shareholder Yield | -403.80% |
| Earnings Yield | -28.41% |
| FCF Yield | -22.04% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Analyst Forecast
The average price target for Oncoinvent ASA is 112.50, which is -20.21% lower than the current price. The consensus rating is "Strong Buy".
| Price Target | 112.50 |
| Price Target Difference | -20.21% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | 44.96% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
The last stock split was on January 19, 2026. It was a reverse split with a ratio of 0.01.
| Last Split Date | Jan 19, 2026 |
| Split Type | Reverse |
| Split Ratio | 0.01 |
Scores
Oncoinvent ASA has an Altman Z-Score of -0.98 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.98 |
| Piotroski F-Score | 1 |